NO943653L - Rekombinante, humane HIV-nöytraliserende monoklonale antistoffer for forebyggelse og behandling av HIV-infeksjon - Google Patents

Rekombinante, humane HIV-nöytraliserende monoklonale antistoffer for forebyggelse og behandling av HIV-infeksjon

Info

Publication number
NO943653L
NO943653L NO943653A NO943653A NO943653L NO 943653 L NO943653 L NO 943653L NO 943653 A NO943653 A NO 943653A NO 943653 A NO943653 A NO 943653A NO 943653 L NO943653 L NO 943653L
Authority
NO
Norway
Prior art keywords
prevention
treatment
monoclonal antibodies
hiv
neutralizing monoclonal
Prior art date
Application number
NO943653A
Other languages
English (en)
Other versions
NO943653D0 (no
Inventor
Emilio A Emini
Anthony J Conley
George E Mark
L Syd Johnson
David S Pfarr
Original Assignee
Merck & Co Inc
Medimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Medimmune Inc filed Critical Merck & Co Inc
Publication of NO943653D0 publication Critical patent/NO943653D0/no
Publication of NO943653L publication Critical patent/NO943653L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Rekombinante, humane HTV-naytraliserende monoklonale antistoffer for forebyggelse og behandling av HTV-infeksjon Rekombinante, humane immun- globulinmolekyler som er nøytraliser- ende for HIV-1, fremgangsmåter for fremstilling av immunglobulinene og fremgangsmåter for forebyggelse av HIV- 1-infeksjon ved anvendelse av immunglo- bulinene. DNA-konstruksjoner innehold- ende de komplementaritetsbestemmende områder (CDR) og rammeverk (FR) for det native, humane antistoff, kombineres med andre konstante områder og uttryk- kes i rekombinante vertsceller. Disse rekombinante antistoffer er anvendelige for behandling og forebyggelse av HIV- 1-infeksjon in vlvo.
NO943653A 1992-04-01 1994-09-30 Rekombinante, humane HIV-nöytraliserende monoklonale antistoffer for forebyggelse og behandling av HIV-infeksjon NO943653L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86170192A 1992-04-01 1992-04-01
PCT/US1993/002629 WO1993019785A1 (en) 1992-04-01 1993-03-23 Recombinant human hiv-neutralizing monoclonal antibodies for prevention and treatment of hiv infection

Publications (2)

Publication Number Publication Date
NO943653D0 NO943653D0 (no) 1994-09-30
NO943653L true NO943653L (no) 1994-11-30

Family

ID=25336532

Family Applications (1)

Application Number Title Priority Date Filing Date
NO943653A NO943653L (no) 1992-04-01 1994-09-30 Rekombinante, humane HIV-nöytraliserende monoklonale antistoffer for forebyggelse og behandling av HIV-infeksjon

Country Status (19)

Country Link
EP (1) EP0577243A3 (no)
JP (1) JPH06217791A (no)
KR (1) KR950700761A (no)
CN (1) CN1081716A (no)
AU (2) AU3928593A (no)
BG (1) BG99074A (no)
CA (1) CA2093099A1 (no)
CZ (1) CZ239694A3 (no)
FI (1) FI944561A0 (no)
HU (1) HUT70461A (no)
IL (1) IL105145A0 (no)
MX (1) MX9301858A (no)
NO (1) NO943653L (no)
NZ (1) NZ251582A (no)
RU (1) RU94045907A (no)
SK (1) SK116294A3 (no)
WO (1) WO1993019785A1 (no)
YU (1) YU22693A (no)
ZA (1) ZA932308B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE390441T1 (de) * 1998-10-30 2008-04-15 Novozymes As Niedrigallergene proteinvarianten
US7067148B2 (en) 2001-02-15 2006-06-27 King Pharmaceutical Research & Development, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US7560529B2 (en) 2001-04-24 2009-07-14 FDS Pharma Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence
RU2221873C2 (ru) * 2001-04-24 2004-01-20 Закрытое акционерное общество "АСГЛ-Фармацевтические Инновации" Способ получения каталитических антител (варианты), антигены для иммунизации и нуклеотидная последовательность
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
FR2844455B1 (fr) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
PT1595959E (pt) * 2003-02-20 2015-03-05 Chemo Sero Therapeut Res Inst Método para melhorar a eficácia de uma preparação de anticorpo monoclonal
BRPI0815743A2 (pt) * 2007-08-24 2015-02-18 Novartis Ag Proteínas hiv env com modificações no laço v3
ES2467108T3 (es) 2008-12-09 2014-06-11 Gilead Sciences, Inc. Moduladores de receptores tipo toll
WO2015117008A2 (en) * 2014-01-31 2015-08-06 The Rockefeller University Broadly neutralizing anti-hiv antibodies and epitope therefor
PT3166607T (pt) * 2014-07-11 2022-12-07 Gilead Sciences Inc Moduladores de receptores de tipo toll para o tratamento do vih
CA2960436C (en) 2014-09-16 2021-01-05 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
EP4007605A4 (en) * 2019-08-01 2023-08-16 Momenta Pharmaceuticals, Inc. ANTI-FCRN ANTIBODIES AND METHODS OF USE THEREOF
WO2021227138A1 (zh) * 2020-05-09 2021-11-18 江苏省疾病预防控制中心(江苏省公共卫生研究院) 针对新型冠状病毒的单克隆抗体或其抗原结合部分
CN118666967B (zh) * 2024-03-06 2025-03-28 广东医保药业有限公司 多肽及其与头孢噻肟舒巴坦的组合

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0366718B1 (en) * 1987-05-29 1995-05-10 Tanox Biosystems, Inc. Monoclonal antibodies neutralizing hiv-1
EP0311228A3 (en) * 1987-10-09 1990-05-02 Repligen Corporation Recombinant polypeptides and their uses, including assay for aids virus
IL94624A0 (en) * 1989-06-05 1991-04-15 Repligen Corp Human monoclonal antibodies to hiv-1 mn qq120
AU8228791A (en) * 1990-06-15 1992-01-07 New York University Heterohybridomas producing human monoclonal antibodies to hiv-1
JPH07505051A (ja) * 1992-01-29 1995-06-08 アメリカ合衆国 Ｈｉｖ−１ｅｎｖ及びｎｅｆタンパク質に対して局部的相同性を有するタンパク質，ａａｍｐ−１

Also Published As

Publication number Publication date
NZ251582A (en) 1997-07-27
YU22693A (sh) 1997-01-08
FI944561A7 (fi) 1994-09-30
FI944561L (fi) 1994-09-30
WO1993019785A1 (en) 1993-10-14
HU9402824D0 (en) 1994-11-28
HUT70461A (en) 1995-10-30
AU658987B2 (en) 1995-05-04
SK116294A3 (en) 1996-11-06
BG99074A (bg) 1995-11-30
AU3928593A (en) 1993-11-08
CN1081716A (zh) 1994-02-09
ZA932308B (en) 1994-09-30
EP0577243A3 (en) 1994-11-02
FI944561A0 (fi) 1994-09-30
NO943653D0 (no) 1994-09-30
AU3563093A (en) 1993-10-07
RU94045907A (ru) 1996-11-10
CZ239694A3 (en) 1995-07-12
KR950700761A (ko) 1995-02-20
CA2093099A1 (en) 1993-10-02
MX9301858A (es) 1994-03-31
EP0577243A2 (en) 1994-01-05
JPH06217791A (ja) 1994-08-09
IL105145A0 (en) 1993-07-08

Similar Documents

Publication Publication Date Title
NO943653L (no) Rekombinante, humane HIV-nöytraliserende monoklonale antistoffer for forebyggelse og behandling av HIV-infeksjon
ATE512224T1 (de) Rekonstituierter menschlicher anti-hm.1 antikörper
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
DK0626447T3 (da) Monoklonale antistoffer og Fv, som er specifikke for CD2-antigen
DK1140170T3 (da) Antistoffragmenter til topisk behandling af öjensygdomme
PT712863E (pt) Anticorpos monoclonais humanizados e quimericos que reconhecem o receptor do factor de crescimento epidermico (egf-r); utilizacao diagnostica e terapetica
ATE373712T1 (de) Natürlicher menschlicher antikörper
DK0666868T4 (da) Anvendelse af anti-VEGF-antistoffer til behandling af cancer
PT699237E (pt) Fvs de cadeia anti-egfr e anticorpos anti-egfr
CA2310888A1 (en) Monoclonal human natural antibodies
ES2145004T3 (es) Derivados de anticuerpos.
SE8703225L (sv) Monoklonala antikroppar och peptider anvendbara vid behandling och diagnostisering av hiv-infektioner
MC2308A1 (fr) Peptides utilises dans la vaccination et l'induction d'anticorps neutralisant contre le virus de l'immunodeficience humaine
DK0546076T3 (da) Anvendelse af anti-ICAM antistoffer til fremstilling af et lægemiddel til behandling af endotoksiskshock
DE69029858D1 (de) Behandlung von einer autoimmun-krankheit
DE69333484D1 (de) Umgestaltete monoklonale Antikörper gegen ein Immunglobulinisotyp
EA200200974A1 (ru) Моноклональные антитела к рецептору лпнп человека, их получение и применение
SE9201281D0 (sv) New human monoclonal antibodies, and a method for preparation thereof
DE69941051D1 (de) Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisier
NO984851L (no) DHEA kombinasjonsterapi
NO924803L (no) Tumor-relatert monoklonalt antistoff 88bv59

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application